M
Myron Schwartz
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 484
Citations - 43786
Myron Schwartz is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 85, co-authored 447 publications receiving 37628 citations. Previous affiliations of Myron Schwartz include New York University & Saint Louis University.
Papers
More filters
Journal ArticleDOI
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.
Journal ArticleDOI
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
Vincenzo Mazzaferro,Josep M. Llovet,Rosalba Miceli,Sherrie Bhoori,M. Schiavo,Luigi Mariani,Tiziana Camerini,Sasan Roayaie,Myron Schwartz,Gian Luca Grazi,René Adam,Peter Neuhaus,Mauro Salizzoni,Jordi Bruix,Alejandro Forner,Luciano De Carlis,Umberto Cillo,Andrew K. Burroughs,Roberto Troisi,Massimo Rossi,Giorgio Enrico Gerunda,Jan Lerut,Jacques Belghiti,Ilka de Fátima Santana Ferreira Boin,Jean Gugenheim,Fedja Rochling,Bart van Hoek,Pietro Majno +27 more
TL;DR: More patients with hepatocellular carcinoma could be candidates for transplantation if the current dual approach to candidacy, based on the strict Milan criteria, were replaced with a more precise estimation of survival contouring individual tumour characteristics and use of the up-to-seven criteria.
Journal ArticleDOI
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Josep M. Llovet,Adrian M. Di Bisceglie,Jordi Bruix,Barnett S. Kramer,Riccardo Lencioni,Andrew X. Zhu,Morris Sherman,Myron Schwartz,Michael Lotze,Jayant A. Talwalkar,Gregory J. Gores +10 more
TL;DR: These guidelines provide a common framework for designing trials to facilitate comparability of results, and randomized phase 2 trials with a time-to-event primary endpoint, such as time to progression, are pivotal in clinical research on HCC.
Journal ArticleDOI
Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
Yujin Hoshida,Augusto Villanueva,Masahiro Kobayashi,Judit Peix,Derek Y. Chiang,Amy L. Camargo,Supriya Gupta,Jamie Moore,Matthew J. Wrobel,Jim Lerner,Michael R. Reich,Jennifer A. Chan,Jonathan N. Glickman,Kenji Ikeda,Masaji Hashimoto,Goro Watanabe,Maria Grazia Daidone,Sasan Roayaie,Myron Schwartz,Swan N. Thung,Helga B. Salvesen,Stacey Gabriel,Vincenzo Mazzaferro,Jordi Bruix,Scott L. Friedman,Hiromitsu Kumada,Josep M. Llovet,Todd R. Golub +27 more
TL;DR: The feasibility of genomewide expression profiling of formalin-fixed, paraffin-embedded tissues is demonstrated and it is shown that a reproducible gene-expression signature correlated with survival is present in liver tissue adjacent to the tumor in patients with hepatocellular carcinoma.
Journal ArticleDOI
Resection and liver transplantation for hepatocellular carcinoma.
TL;DR: Intention-to-treat analysis has shown that wide extended indications lead to 25% 5-year survival rates, and molecular markers are needed to better select the candidates for surgery.